10-Q: Celcuity Secures FDA Approval for REVTORPYK, Eyes Market Launch

Celcuity Inc. announced FDA approval for its REVTORPYK (gedatolisib) therapy for HR+/HER2- advanced breast cancer, alongside robust clinical trial results and significant capital raises.

Summary

• Celcuity Inc. has received FDA approval for its product REVTORPYK (gedatolisib) for adult patients with HR+/HER2- advanced breast cancer (ABC) who have progressed after endocrine therapy.
• The approval is based on positive results from the VIKTORIA-1 Phase 3 clinical trial, specifically the PIK3CA Wild-Type (WT) cohort.
• The company also announced positive topline results from the PIK3CA Mutant-Type (MT) cohort of the VIKTORIA-1 trial, showing significant improvements in progression-free survival (PFS) and objective response rate (ORR) compared to alpelisib.
• Celcuity has commenced commercial launch activities for REVTORPYK, with shipments expected in late Q3 2026.
• The company raised substantial capital through the issuance of $575.0 million in 0.250% Convertible Senior Notes due 2032 and $201.3 million in 2.750% Convertible Senior Notes due 2031.
• A voluntary prepayment of $137.4 million was made on the Amended A&R Loan Agreement using proceeds from the 2032 Notes.
• Research and development expenses decreased by 15% year-over-year for the three months ended June 30, 2026, while selling, general, and administrative expenses increased significantly by 361% due to commercialization efforts.
• The company reported a net loss of $78.9 million for the three months ended June 30, 2026, and has an accumulated deficit of $580.6 million as of June 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to the FDA approval of REVTORPYK and strong clinical trial data, despite ongoing operational losses.

Positives

• FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- advanced breast cancer.
• Positive Phase 3 clinical trial data (VIKTORIA-1) demonstrating significant improvements in PFS and ORR for both PIK3CA WT and MT cohorts.
• REVTORPYK recommended by NCCN as a preferred Category 1 second-line and/or subsequent-line therapy.
• Commercial launch activities for REVTORPYK have commenced, with shipments expected late Q3 2026.
• Successful completion of $575.0 million in 0.250% Convertible Senior Notes due 2032 and $201.3 million in 2.750% Convertible Senior Notes due 2031, bolstering liquidity.
• Cash, cash equivalents, and short-term investments totaled $754.0 million as of June 30, 2026, providing runway into 2029.
• Expanded Access Program (EAP) opened in August 2026 to provide early patient access to gedatolisib.
• Gedatolisib demonstrated a superior safety profile compared to oral PI3K/mTOR inhibitors in clinical trials.

Negatives

• Continued significant operating losses, with a net loss of $78.9 million for the three months ended June 30, 2026.
• Accumulated deficit of $580.6 million as of June 30, 2026.
• Substantial increase in Selling, General, and Administrative (SG&A) expenses (361% for the quarter) driven by commercialization efforts, impacting profitability.
• Loss on debt extinguishment of $11.5 million related to the prepayment of the Amended A&R Loan Agreement.
• The company has not generated any revenue from product sales to date.
• Significant ongoing investment required for clinical trials (VIKTORIA-2, CELC-G-201) and commercialization.

Risks

• Potential inability to achieve broad market adoption of REVTORPYK.
• Uncertainty and costs associated with clinical studies and the development and commercialization of pharmaceuticals.
• Challenges in demonstrating the safety and sufficient magnitude of benefit for future regulatory approvals (sNDAs).
• Difficulties in managing growth, including hiring and retaining a qualified sales force and attracting key personnel.
• Changes in government regulations affecting operations.
• Tightening credit markets and limitations on access to capital.
• Stock market volatility or other factors affecting the ability to access capital on favorable terms.
• Obtaining and maintaining intellectual property protection for REVTORPYK and future formulations.

Future Outlook

Celcuity expects to generate revenue from REVTORPYK sales commencing in the third quarter of 2026. The company anticipates increased R&D and SG&A expenses to support commercialization, ongoing clinical trials, and business development. Current capital resources are expected to fund operations at least into 2029, but additional capital may be sought.

Management Comments

• The Company believes its existing cash, cash equivalents and short-term investments will be sufficient to fund planned operations for at least one year from the issuance of these unaudited condensed financial statements.
• We believe that our current cash, cash equivalents and short-term investments, will provide sufficient cash to finance our operations at least into 2029.
• Additional capital may not be available on reasonable terms, or at all.

Industry Context

StockSavvy.ai notes that Celcuity's FDA approval for REVTORPYK positions it within the competitive but high-growth oncology market, specifically in advanced breast cancer. The company's differentiated approach to targeting the PI3K/AKT/mTOR pathway and its positive Phase 3 data suggest a strong potential to capture market share, especially given the unmet need for effective treatments post-endocrine therapy.

Comparison to Industry Standards

• The hazard ratios for the gedatolisib triplet (0.24 for WT, 0.50 for MT) and doublet (0.33 for WT, 0.51 for MT) in the VIKTORIA-1 trial are reported as more favorable than any previously reported Phase 3 trial for patients with HR+/HER2- ABC receiving at least their second line of therapy.
• The incremental improvements in median PFS (7.3 months for triplet, 5.4 months for doublet in WT cohort) over fulvestrant are higher than previously reported in Phase 3 trials for this patient population.
• The ORR of 49% for the gedatolisib triplet in the PIK3CA MT cohort is the highest reported by any Phase 3 clinical trial for a regimen including endocrine therapy in second-line HR+/HER2- ABC.
• The median PFS of 11.1 months for the gedatolisib triplet in the PIK3CA MT cohort is the highest reported by any Phase 3 trial for patients with HR+/HER2- ABC receiving a regimen including endocrine therapy as second-line treatment.
• Gedatolisib is the first inhibitor targeting the PAM pathway to demonstrate positive Phase 3 results in patients with HR+/HER2- PIK3CA WT ABC whose disease progressed on or after treatment with a CDK4/6 inhibitor.
• The company's ability to achieve FDA approval and subsequent NCCN recommendation positions REVTORPYK favorably against other treatments in the advanced breast cancer landscape.

Legal Proceedings

• No legal proceedings are currently expected to have a material adverse effect on the business, financial condition, or results of operations.

Stakeholder Impact

• Shareholders: Potential for significant value creation due to FDA approval and commercialization of REVTORPYK, offset by ongoing losses and dilution risk from potential future capital raises.
• Patients: Access to a new, potentially more effective treatment option for advanced breast cancer (REVTORPYK) and early access through the Expanded Access Program.
• Healthcare Providers: Availability of a recommended therapy (NCCN Category 1) for HR+/HER2- ABC.
• Payors: Need to establish reimbursement for REVTORPYK, which will be crucial for commercial success.

Next Steps

• Commence commercial launch activities for REVTORPYK, with shipments expected late in the third quarter of 2026.
• Submit data from Study 2 (PIK3CA MT cohort) of the VIKTORIA-1 Phase 3 clinical trial to the FDA as a supplemental New Drug Application (sNDA) in Q3 2026.
• Submit VIKTORIA-1 Phase 3 clinical trial data to other regulatory authorities outside the U.S. following the sNDA submission.
• Continue Phase 3 clinical trials for VIKTORIA-2 (expected topline data by end of 2028 for Study 1, 2030 for Study 2).
• Continue Phase 1b/2 clinical trial for CELC-G-201 in mCRPC, with updated data expected in Q4 2026.
• Continue development of subcutaneous gedatolisib formulation.
• Potentially raise additional capital to fund future operations and growth.

Key Dates

Recommendation

The FDA approval of REVTORPYK, supported by strong Phase 3 data and a favorable NCCN recommendation, represents a significant de-risking event and a major catalyst for future revenue generation. The substantial capital raised provides ample runway for commercialization and ongoing clinical development. While operating losses persist, the commercial potential of REVTORPYK in a large market, coupled with the company's robust clinical pipeline, justifies a strong buy recommendation for investors with a long-term horizon.

Keywords

REVTORPYK, gedatolisib, breast cancer, PI3K inhibitor, mTOR inhibitor, oncology, clinical trials, FDA approval